Pyxis Oncology, Inc. (PYXS)
Health Care · Oncology-focused biotechnology; antibody-drug conjugates · Nasdaq
Clinical-stage biotech advancing a novel ADC that targets fibronectin in the tumor microenvironment to treat solid tumors, particularly head and neck cancer.
What Pyxis Oncology, Inc. does
Pyxis Oncology is a clinical-stage oncology company developing novel antibody-drug conjugates (ADCs) to treat solid tumors. The company's lead product candidate, micvotabart pelidotin (MICVO), is an investigational ADC that targets extradomain-B fibronectin (EDB+FN) in the tumor microenvironment and is currently in Phase 1 trials for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) both as monotherapy and in combination with pembrolizumab (KEYTRUDA®).
Themes: ["ADC / antibody-drug conjugates","Oncology / solid tumors","Head and neck cancer (HNSCC)","Tumor microenvironment targeting","Immuno-oncology"]
Fundamentals
- Price$2.67 as of 2026-07-10 close
- Market cap$169M as of 2026-07-13
- 1-year return+124.4% as of 2026-07-10 close
- Net margin-574.5% as of 2026-07-13
- Gross margin+82.8% as of 2026-07-13
- ROE-70.8% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)-14.2% as of 2026-07-13
- Beta1.30 as of 2026-07-13
Key risks (from latest filing)
["Substantial doubt about ability to continue as a going concern; requires additional capital to finance operations over several years","Lead product candidate MICVO is in early-stage clinical development with uncertain outcome; failure in clinical trials or inability to obtain regulatory approval would materially harm the company","Dependence on third-party manufacturers and critical license agreements (including Pfizer license); breach of these agreements could prevent development and commercialization of MICVO"]
Competitors & peers
- Genmab
- Daiichi Sankyo
- Seattle Genetics/Seagen
- Pfizer (oncology ADC programs)
- Celldex Therapeutics
- Mersana Therapeutics
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.